Elevated expression of YAP has been identified in varioushuman cancers, and as YAP inhibitor development is very limited, TNKSinhibition could be a valid alternative for hampering YAP oncogenicproperties.66 Several TNKS inhibitors havebeen developed67,68 such as compounds E744969 and STP100270 (structureundisclosed), which have progressed in clinical studies, even if compoundE7449 behaves as a dual TNKS1–2 and PARP1–2 inhibitor.Other TNKS inhibitors such as RK287107 (1)71 and OM-153 (2)72 are being evaluated in preclinical studies. This evidence concerns the gene PARP1 and cancer.